Journal: bioRxiv

Article Title: BIOPRINTING OF MICRODISSECTED TUMOR “CUBOIDS” IN HYDROGELS

doi: 10.1101/2025.09.05.671932

Figure Lengend Snippet: (A) Brightfield and Sytox Green nuclear cell death dye images of Py8119 tumor cuboids in cuboid dots after 3 days of treatment with cisplatin or medium control. (B) Brightfield and RedDot2 nuclear cell death images after 3 days of treatment with doxorubicin or DMSO vehicle control. (C) Graph of cell death after cisplatin treatment. (D) Graph of cell death after doxorubicin treatment. Number of cuboids per condition shown in parentheses underneath each condition. * = p<.05 **=p< .01 One-way ANOVA with Dunnett’s Multiple Comparison test.

Article Snippet: To perform the cell death assay, we exposed the cuboid dots to fluorescent dead nuclear stains, SYTOX green (SG; Invitrogen, 0.01 μM) or Reddot2 (1:400 dilution, Invitrogen) for 2 hrs, followed by three washes with PBS.

Techniques: Control, Comparison

Journal: PLOS One

Article Title: Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV

doi: 10.1371/journal.pone.0338127

Figure Lengend Snippet: A. Competitive ELISA assessing the binding of His-tagged IgGs to immobilized HER2 in the presence or absence of saturating concentrations of non-His-tagged IgGs, detected with an anti-His-HRP antibody. B. Saturation binding curves of trastuzumab and pertuzumab to HER2 on live MCF7 cells. Cells were incubated with antibodies (0-400 nM) for 30 min and detected with an AF647-conjugated goat anti-human secondary antibody via flow cytometry. C. Competitive binding of of AF647-labeled trastuzumab or pertuzumab (0-300 nM) to MCF7 cells pre-saturated with 267 nM of unlabeled trastuzumab and pertuzumab, analyzed by flow cytometry. D. Binding of AF647-conjugated m66 or m75 to MCF7 cells after pre-incubation with 267 nM trastuzumab or pertuzumab. E. Binding of AF647-conjugated rabbit antibodies to MCF7 cells pre-saturated with 267 nM of trastuzumab and pertuzumab, evaluated by flow cytometry. T, trastuzumab; P, pertuzumab. Error bars, SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, T-test.

Article Snippet: Briefly, each antibody was reacted with 20 molar equivalents of AF647 NHS ester (Biotium, 30–3007) for 2 h at room temperature protected from light.

Techniques: Competitive ELISA, Binding Assay, Incubation, Flow Cytometry, Labeling

Journal: Cell Reports Methods

Article Title: CUBIC-Cloud provides an integrative computational framework toward community-driven whole-mouse-brain mapping

doi: 10.1016/j.crmeth.2021.100038

Figure Lengend Snippet: Whole-brain analysis of input cell populations projecting to ARH Kiss1+ neurons (A) Virus injection scheme. AAV carrying mCherry, TVA receptor, and optimized glycoprotein (oG) was injected into the ARH of Kiss1-Cre transgenic mouse, followed by injection of modified rabies virus carrying GFP. Cells expressing both mCherry and GFP are the starter cells. (B) Quantification of starter cell localization. The ratio was computed by dividing the cell count in each region by the total number of starter cells. The total number of starter cells in each sample is shown on the right end of the heatmap. (C) Whole-brain view of all input cells. (D) Total cell count and the distribution of input cells. Only male brains were considered here. (E) Cell-density heatmap of all brain regions (excluding the isocortex and cerebellum, where virtually no input cells were detected). The means of male and female brains are shown. (F) The plot shows extremely sparse input cell populations in previously unidentified brain regions (n = 3). Only male brains were considered here. Data are shown and mean ± SD (n = 3). (G) Raw GFP (black) and nuclear staining (RedDot2, purple) images showing the regions identified in (F). Macro views (top) and zoomed-in views (of boxed areas; bottom) are shown. Brain region acronyms follow the ontology defined by the Allen Brain Atlas.

Article Snippet: For each dye/FP, the following laser and fluorescence filter pair was used: Alexa 594 [Ex: 594 nm, Em: 641/75 nm bandpass (FF02-641/75-32, Semrock)], Cy3 [Ex: 532 nm, Em: 585/40 nm bandpass (FF01-585/40-32, Semrock)], SYTOX-G, BOBO-1 and GFP [Ex: 488 nm, Em: 520/40 nm bandpass (FF01-520/44-32, Semrock)], RedDot2 [Ex: 642nm, Em: 708/75 nm bandpass (FF01-708/75-32, Semrock)], mCherry [Ex: 594 nm, Em: 628/32 nm bandpass (FF01-628/32-32, Semrock)].

Techniques: Injection, Transgenic Assay, Modification, Expressing, Cell Counting, Staining